Catechol-O-Methyltransferase Inhibition in Neurological Disorders

Catechol-O-methyltransferase (COMT) is a pivotal enzyme in the metabolism of catecholamines, including dopamine, epinephrine and noradrenaline. By transferring a methyl group from S-adenosyl-L-methionine (SAM) to catechol substrates, COMT regulates synaptic neurotransmitter levels and thereby influences motor control, cognition and pain perception. Genetic polymorphisms such as Val158Met modulate COMT activity and have been linked to psychiatric vulnerability, pain sensitivity and individual responses to levodopa therapy in Parkinson’s disease. Inhibitors of COMT enhance central and peripheral dopamine availability, prolonging the efficacy of levodopa, attenuating motor fluctuations and offering potential benefit in other neuropsychiatric conditions. Advances in structural biology, medicinal chemistry and natural product screening have yielded diverse inhibitor classes, yet challenges remain in balancing potency, brain penetrance, safety and selectivity across COMT isoforms.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Catechol-O-Methyltransferase Inhibition in Neurological Disorders publication trend

The graph below shows the total number of articles in catechol-o-methyltransferase inhibition in neurological disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Catechol-O-methyltransferase (COMT): An enzyme that inactivates catecholamines by transferring a methyl group from S-adenosyl-L-methionine to the catechol moiety.

S-adenosyl-L-methionine (SAM): A universal methyl donor cofactor used by methyltransferases for biological methylation reactions.

Uncompetitive inhibitor: A type of enzyme inhibitor that binds only to the enzyme-substrate complex, reducing both maximum velocity and substrate affinity.

Non-competitive inhibitor: An inhibitor that binds to an enzyme at a site distinct from the substrate binding site, decreasing catalytic efficiency without affecting substrate affinity.

Blood-brain barrier (BBB): A selective endothelial interface that restricts passage of substances from the bloodstream into the central nervous system.

IC₅₀: The concentration of an inhibitor required to reduce an enzyme’s activity by 50%, commonly used to compare potencies of pharmacological agents.

References

1. Inhibition of catechol-O-methyltransferase by natural pentacyclic triterpenes: structure–activity relationships and kinetic mechanism. Journal of Enzyme Inhibition and Medicinal Chemistry (2021).
2. Tissue and interspecies comparison of catechol-O-methyltransferase mediated catalysis of 6-O-methylation of esculetin to scopoletin and its inhibition by entacapone and tolcapone. Xenobiotica (2020).
3. 1-Hydroxy-2(1H)-pyridinone-Based Chelators with Potential Catechol O-Methyl Transferase Inhibition and Neurorescue Dual Action against Parkinson’s Disease. Molecules (2022).